Selected article for: "binding affinity and docking study"

Author: jose-carlos Valle-Casuso; Delphine Gaudaire; Lydie Martin-Faivre; anthony madeline; Patrick Dallemagne; Stephane Pronost; Helene Munier-Lehmann; Stephan Zientara; Pierre-Olivier Vidalain; Aymeric Hans
Title: Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors
  • Document date: 2020_4_10
  • ID: my4n0vye_1
    Snippet: Viruses with a RNA genome infect both animals and plants, and dominate the eukaryotic virome by 57 their diversity and deleterious effects 1 Previous works exploring EAV inhibitors have proposed to use morpholino or peptide-conjugated 80 morpholino oligomers specifically designed against the EAV genome as a therapy to impair viral 81 replication 8 . However, this promising therapy is not easily applicable for use in vivo in large animal 82 such a.....
    Document: Viruses with a RNA genome infect both animals and plants, and dominate the eukaryotic virome by 57 their diversity and deleterious effects 1 Previous works exploring EAV inhibitors have proposed to use morpholino or peptide-conjugated 80 morpholino oligomers specifically designed against the EAV genome as a therapy to impair viral 81 replication 8 . However, this promising therapy is not easily applicable for use in vivo in large animal 82 such as horses. Although, two effective EAV vaccines have been available since 1985, the proportion 83 of horses vaccinated against EAV in the equine population remains insufficient to control the disease 84 9 . We think that a complementary approach using antiviral molecules would be ideal to complement 85 author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • antiviral molecule and RNA genome: 1, 2, 3
    • antiviral molecule and RNA genome virus: 1
    • complementary approach and disease control: 1
    • complementary approach and previous work: 1
    • complementary approach and RNA genome: 1, 2, 3
    • complementary approach and RNA genome virus: 1, 2
    • deleterious effect and previous work: 1
    • deleterious effect and promising therapy: 1
    • deleterious effect and RNA genome: 1, 2
    • deleterious effect and RNA genome virus: 1
    • disease control and insufficient remain: 1
    • disease control and large animal: 1, 2, 3, 4, 5, 6, 7, 8
    • disease control and plant animal: 1, 2, 3, 4, 5, 6
    • disease control and previous work: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • disease control and RNA genome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • disease control and RNA genome virus: 1
    • EAV genome and morpholino oligomer: 1
    • EAV genome and RNA genome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • EAV genome and RNA genome virus: 1, 2, 3